卡培他滨联合多西紫杉醇一线治疗晚期胃癌的临床观察

目的 探讨卡培他滨联合多西紫杉醇一线治疗晚期胃癌的近期疗效、不良反应及生存情况。方法 2010年1月至2012年7月共24例晚期胃癌患者采用卡培他滨联合多西紫杉醇一线化疗，具体方案为：卡培他滨1000mg／m2口服，每天2次，d1～d14；多西紫杉醇75mg／m2静滴1h，d1，或者多西紫杉醇35mg／m2静滴1h，d1、d8。21天为1周期，至少化疗2个周期。2个周期评价疗效，每周期评价不良反应。结果 24例患者均可评价疗效。无CR病例，获PR 3例，SD 20例，PD 1例；有效率为12.5％，疾病控制率为95.8％。中位总生存时间为10.5个月（95％CI：2.47～18.47个月）；10例患者死于疾病进展，其中7例的疾病进展时间为1.7～15.2个月。主要不良反应为骨髓抑制和手足综合征，以1～2级为主，全组患者无治疗相关性死亡。结论 卡培他滨联合多西紫杉醇一线治疗晚期胃癌的疗效确切，不良反应可耐受，值得深入研究。

Clinical observation of capecitabine plus docetaxel for the first-line treatment of advanced gastric cancer

Objective To evaluate the efficacy, side effects and survival of capecitabine plus docetaxel for the first-line treat- ment of advanced gastric cancer. Methods From January 2010 to July 2012, 24 cases of advanced gastric cancer were enrolled to re- ceive capecitabine plus doeetaxel regimen. Treatment consisted of 3-week cycles of twice-daily eapecitabin 1000mg/m2 （on days 1-14） and intravenous docetaxel 75mg/mz lh, dlOr 35mg/m21h, d1 , d8. Each patient received at least 2 cycles. The efficacy was evaluated every two cycles and side effects were evaluated each cycle. Results The efficacy could be evaluated in 24 patients, none of them a- chieved complete responses, 3 showed partial responses, 20 had stable disease, and 1 got progressive disease. The response rate was 12.5% and the disease control rate was 95.8%. The median overall survival was 10. 5 months（95% CI： 2.47-18.47months）. Ten patients died fi＇om disease progression, and the time to progression of 7 patients was 1.7-15.2months. The main side effects were my- elosuppression and hand-foot syndrome, mainly in grade 1-2, and none of them suffered treatment related death. Conclusion Capeeitabine plus docetaxel regimen for the first-line treatment of advanced gastric cancer has a definite effect with acceptable toxicity, which is worth further study.